DCTS

THREAD and Amazon Web Services Modernize Clinical Research with Launch of Cloud-based, AI-driven Decentralized Clinical Trials Technology

Retrieved on: 
Tuesday, March 29, 2022
DCTS, Guest appearance, CARY, DCT, Automation, Caregiver, Cros, Health care, SDV, Research, AI, Precision medicine, CEO, Technology, Machine learning, Amazon Web Services, Architecture, List of life sciences, AWS, Clinical trial, Frost & Sullivan, JLL Partners, Patient, Medical device

CARY, N.C., March 29, 2022 /PRNewswire/ -- THREAD®, the leading technology and consulting service provider enabling electronic clinical outcome assessments (eCOA) and decentralized clinical trials (DCTs), announced today that it is collaborating with Amazon Web Services, Inc. (AWS) to launch enhancements to the THREAD platform powered by enterprise-scale automation and built-in AI-driven technologies. These next-generation DCT technology features will serve as the backbone for modern clinical research by enabling faster, more efficient clinical trials while improving access for research participants with higher quality data capture across the life cycle of a study.

Key Points: 
  • THREAD is working with AWS Professional Services experts to design an advanced machine learning architecture and industry-leading AI models to automate processes for customers.
  • THREAD's new cloud-enabled platform features will accelerate clinical research by reducing inefficiencies in real-time data capture, auto-populating data workflows that are completed manually today and more.
  • "Our technology innovations are revolutionizing today's clinical research by helping our customers to design, operate, and scale modern clinical trial approaches," said John Reites, CEO, THREAD.
  • THREAD is the industry-leading decentralized clinical trials technology and consulting service provider, helping biopharma and CROs decentralize clinical research and enable electronic clinical outcome assessments (eCOA) for sites, participants, caregivers, and home health professionals.

Curebase Rapidly Reaches Growth Milestone

Retrieved on: 
Tuesday, March 15, 2022
Growth, FDA, Time, Lviv, Physician, GGV Capital, Technology, DCT, Culture, Cros, SAN, Patient, Communication, Research, Marketing, DCTS, Pharmaceutical industry

SAN FRANCISCO, March 15, 2022 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, has attained a growth milestone by hiring the 100th member of its team less than a year after the startup raised Series A financing. 

Key Points: 
  • SAN FRANCISCO, March 15, 2022 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, has attained a growth milestone by hiring the 100thmember of its team less than a year after the startup raised Series A financing.
  • Six months after a May 2021 series A investment round, Curebase was at 140% staff growth.
  • "It's exciting because the growth is occurring across all departments software, quality, information security, clinical operations, business development and marketing.
  • In addition to its product-centric approach, Lemberg said, Curebase has benefited by building a culture of collaboration across the company.

H Clinical Announces Expansion of Logistics to Better Facilitate Decentralized Clinical Trials

Retrieved on: 
Tuesday, March 8, 2022
Sea shanty, Clinical trial, Patient, Central, CEO, DCTS, Rio Grande, Infection, View, GCP, Multimedia, Pharmaceutical industry

TAMPA, Fla., March 8, 2022 /PRNewswire/ -- H Clinical today announced that the company is expanding logistics service capabilities to support decentralized clinical trials (DCTs) in emerging markets throughout Latin America.

Key Points: 
  • TAMPA, Fla., March 8, 2022 /PRNewswire/ -- H Clinical today announced that the company is expanding logistics service capabilities to support decentralized clinical trials (DCTs) in emerging markets throughout Latin America.
  • H Clinical announces expanding logistics service capabilities to support decentralized trials throughout Latin America.
  • H Clinical is the leader in decentralized clinical trial support and home visits in Latin America.
  • Through GCP-trained home health providers, established logistics infrastructure, and clinical trial coverage across 22 countries, H Clinical is bringing clinical research home.

Myonex to Acquire Clinical Trial and Drug Wholesale Business of Hubertus in Berlin

Retrieved on: 
Monday, February 28, 2022
General Health, Health, Pharmaceutical, Clinical Trials, Medical Supplies, Partnership, Pharmacy, DCTS, Family, Clinical trial, DTP, Acquisition, Union, Solution, Doctor of Philosophy, Time, Pharmaceutical industry, Distribution

Myonex, a leading global clinical trial supply company, announces entry into a definitive agreement with the owners of Hubertus Apotheke am Salzufer (Hubertus) to acquire the Clinical Trial and Wholesale Drug Business, located in Berlin, Germany.

Key Points: 
  • Myonex, a leading global clinical trial supply company, announces entry into a definitive agreement with the owners of Hubertus Apotheke am Salzufer (Hubertus) to acquire the Clinical Trial and Wholesale Drug Business, located in Berlin, Germany.
  • Myonex and the owners of Hubertus also have entered a cooperation agreement with the remaining Pharmacy Business of Hubertus to support decentralized clinical trials (DCTs).
  • Hubertus will retain its Pharmacy Business, and Myonex GmbH and Hubertus Apotheke will cooperate closely in a strategic partnership to enable direct to patient (DtP) shipments and additional services for their customers clinical trial supply needs.
  • I am happy that Myonex, a company sharing our values and being family owned as well, will continue the great work weve started as Hubertus 30 years ago in the clinical trial and wholesale business.

THREAD and EVERSANA Announce Industry's First Integrated, Decentralized Registry and Real-World Data (RWD)-Driven Evidence and Commercialization Solution

Retrieved on: 
Wednesday, February 16, 2022
Collection, Patient, Time, Data collection, CEO, Entrepreneurship, Frost & Sullivan, DCTS, Solution, Cros, Clinical trial, RWD, Disease, Janssen, Technology, EMR, LinkedIn, Twitter, Partnership, Privacy, Janssen Pharmaceuticals, Acquisition, Chronic condition, Research, Caregiver, Industry, LLC, Organization, JLL Partners, Pharmaceutical industry, Mobile phone, Medicine, CARY

Data linkages will be performed using Datavant's technology to ensure patient privacy and data security.

Key Points: 
  • Data linkages will be performed using Datavant's technology to ensure patient privacy and data security.
  • Registry data can be further enriched with other RWD assets and are deidentified and linked for analytic access across multiple sources.
  • "Connecting real-world data augments the depth of data on each patient while increasing the cost-efficiency of the entire study."
  • THREAD recently acquired inVibe, the leading voice-powered research and insights technology solution for the life sciences and health care industries.

CenterWatch Announces Measuring Success in Decentralized Trials: Metrics that Drive Improvement Management Report

Retrieved on: 
Tuesday, February 8, 2022
Success, DCTS, DCT, Method, Decentralized Trials & Research Alliance, Pharmaceutical industry, Cryptocurrency

FALLS CHURCH, Va., Feb. 8, 2022 /PRNewswire-PRWeb/ --Measuring Success in Decentralized Trials:

Key Points: 
  • FALLS CHURCH, Va., Feb. 8, 2022 /PRNewswire-PRWeb/ --Measuring Success in Decentralized Trials:
    Ready for the new world of metrics analysis?
  • Use the opportunities within this data and work around the challenges with Measuring Success in Decentralized Trials: Metrics that Drive Improvement.
  • This report provides a set of metrics and guidance to use in evaluating the performance of DCTs so you can maximize trial success.
  • Benefit from all of its possibilities with Measuring Success in Decentralized Trials: Metrics that Drive Improvement.

Medidata Experts Address Operationalizing Decentralized Clinical Trials and AI Predictive Models at SCOPE Conference

Retrieved on: 
Thursday, February 3, 2022
Technology, Clinical Trials, Software, Biotechnology, Training, Health, Pharmaceutical, General Health, Education, Cloud, Risk, Patient, Partnership, Learning, Key, PPD, Summit, SCOPE, Disease, Clinical trial, AI, DELMIA, Dassault Group, Euronext Paris, 3D, SIMULIA, Forecasting, Technology, Research, Data science, Â, DCT, SOLIDWORKS, SVP, Thermo Fisher Scientific, VP, Industry, Digital, DCTS, CATIA, Pharmaceutical industry, Medical imaging, Music, Television, GEOVIA, ENOVIA, Compass, BIOVIA, Medidata Solutions, Medidata, Dassault Systèmes, MEDIDATA, DASSAULT SYSTèMES

Medidata , a Dassault Systmes company, will be sharing insights into new decentralized clinical trials (DCTs) and AI technologies as a signature sponsor of the annual Summit for Clinical Ops Executives (SCOPE), February 7-10.

Key Points: 
  • Medidata , a Dassault Systmes company, will be sharing insights into new decentralized clinical trials (DCTs) and AI technologies as a signature sponsor of the annual Summit for Clinical Ops Executives (SCOPE), February 7-10.
  • Medidata experts will be participating in multiple presentations covering a range of innovative solutions to advance clinical trial planning, management, and operations.
  • Digital capabilities including centralized monitoring, electronic patient-reported outcomes, and wearable sensors are enabling clinical trial decentralization at scale.
  • This session explores how DCTs have evolved and elevated RBQM (risk-based quality management) strategies towards the new normal for clinical operations.

UBC Partners with Seqster to Advance Patient-Centric Clinical Trials

Retrieved on: 
Thursday, February 3, 2022
CEO, Safety, DNA, View, Pharmacy, SAN, Norwich Pharma Services, BLUE, UBC, Software as a service, Technology, RWE, Population, Partnership, List of life sciences, Laika (EHR testing framework), Acquisition, Multimedia, Hospital, DCTS, Medical imaging, Pharmaceutical industry

UBC will utilize the technology to enable clinical and observational research to transition from traditional site-based studies to decentralized clinical trials (DCTs).

Key Points: 
  • UBC will utilize the technology to enable clinical and observational research to transition from traditional site-based studies to decentralized clinical trials (DCTs).
  • In addition, the Seqster platform will facilitate patient recruitment, which is the number one reason most clinical trials fail."
  • With the Seqster technology, UBC can combine nationwide real-time data interoperability plus patient engagement into a single platform and run faster, less expensive, and more effective studies.
  • United BioSource LLC (UBC) is a leader in the biopharmaceutical market which provides integrated clinical, safety, and commercialization services.

Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

Retrieved on: 
Wednesday, February 2, 2022
Biotechnology, General Health, Other Health, Health, Clinical Trials, MAXIS, CEO, Patient, Budget, EDC, Clinical trial, Founder, CSM, Twitter, Technology, Research, COVID-19, Partnership, Program, DCT, CRO, Cros, Solution, Clinical data management, DCTS, Fine chemical

Castor , a leading provider of decentralized and hybrid clinical trial solutions, today announced the official launch of its CRO Partnership program.

Key Points: 
  • Castor , a leading provider of decentralized and hybrid clinical trial solutions, today announced the official launch of its CRO Partnership program.
  • The success of clinical trials relies heavily on the eClinical solutions that support them, making it imperative to implement a flexible, technology-enabled approach.
  • Decentralized clinical trials offer increased patient engagement, convenience, shorter trial times, and allows for a more diverse representation of patients in studies compared to conventional trials.
  • According to a recent industry survey , an estimated 50% of clinical trials will be hybrid or decentralized by 2024.

Medidata Expands and Strengthens Decentralized Clinical Trial (DCT) Capabilities Through Groundbreaking Partnership With Circuit Clinical

Retrieved on: 
Wednesday, January 26, 2022
Software, Research, Other Health, General Health, Mobile, Wireless, Internet, Data Management, Technology, Clinical Trials, Science, Other Technology, Health, Other Science, Cloud, Board of directors, COVID-19, Database, Overalls, Risk, IRO, Dassault Group, Awareness, Degenerative disease, SIMULIA, Diabetes, Patient, Cros, Twitter, 3D, Board, Cardiovascular disease, Research, Cancer, DELMIA, DCTS, Instagram, CATIA, SOLIDWORKS, Clinical trial, LinkedIn, Solution, DCT, Rheumatoid arthritis, Euronext Paris, Learning, Kidney disease, Physician, CEO, Partnership, Pharmaceutical industry, BIOVIA, Compass, Medidata Solutions, ENOVIA, Facebook, GEOVIA, MD, Medidata, Dassault Systèmes, Circuit Clinical, MEDIDATA, DASSAULT SYSTèMES, CIRCUIT CLINICAL

Medidata , a Dassault Systmes company, today announced a groundbreaking and exclusive partnership with Circuit Clinical, an Integrated Research Organization (IRO).

Key Points: 
  • Medidata , a Dassault Systmes company, today announced a groundbreaking and exclusive partnership with Circuit Clinical, an Integrated Research Organization (IRO).
  • Additionally, patients will have the opportunity to provide ratings and reviews of their clinical trial experiences through Circuit Clinicals award-winning TrialJourney system.
  • The combined capabilities of Circuit Clinical and Medidatas software solutions will further the ability to deliver hybrid or fully decentralized trials through Circuit Clinicals Network Health Systems and patient engagement capabilities.
  • Circuit Clinical is committed to transforming the way physicians and their patients find, choose, and participate in clinical research.